Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023)
Palvella Therapeutics (PVLA) posted quarterly Preferred Stock Liabilities of $70.6 million for Q4 2023, little changed year-over-year from $70.6 million in Q4 2022, and little changed quarter-over-quarter from $70.6 million in Q4 2022.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Preferred Stock Liabilities for 2 consecutive years, with $70.6 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Preferred Stock Liabilities changed 0.0% year-over-year to $70.6 million; the TTM figure through Dec 2023 stood at $70.6 million (changed 0.0% YoY), while the FY2023 annual figure was $70.6 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities held at $70.6 million in Q4 2023 per PVLA's latest filing, from $70.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $70.6 million in Q4 2022 and bottomed at $70.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |